Obesity News

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with particular benefit observed for those with severe obesity, a speaker reported.

NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these drugs, according to Christos S. Katsanos, PhD.

NATIONAL HARBOR, Md. — In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline.

NATIONAL HARBOR, Md. — Comprehensive obesity care can treat a multitude of conditions, but it requires a “holistic recipe” of ingredients ranging from clinical education to effective interventions and reimbursement, a speaker said.

NATIONAL HARBOR, Md. — AI is “up and coming” across health care, and obesity medicine is no exception, according to Angela Fitch, MD, FACP, MFOMA.

Medicare Part D coverage of obesity medications could lead to a large increase in health care costs due to the prices of the drugs, according to data from a microsimulation model published in JAMA Health Forum.

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for weight loss, according to a study published in Annals of Internal Medicine.

The HHS secretary and FDA commissioner announced several measures to phase out petroleum-based synthetic dyes from the U.S. food supply by the end of next year while transitioning to new natural additives.

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, according to data from two European Congress on Obesity abstracts.